Literature DB >> 31304429

Biogenic Aldehyde-Mediated Mechanisms of Toxicity in Neurodegenerative Disease.

Brianna S Cagle1, Rachel A Crawford1, Jonathan A Doorn1.   

Abstract

Oxidative decomposition of several biomolecules produces reactive aldehydes. Monoamine neurotransmitters are enzymatically converted to aldehydes via monoamine oxidase followed by further metabolism such as carbonyl oxidation/reduction. Elevated levels of aldehyde intermediates are implicated as factors in several pathological conditions, including Parkinson's disease. The biogenic aldehydes produced from dopamine, norepinephrine and serotonin are known to be toxic, generate reactive oxygen species and/or cause aggregation of proteins such as α-synuclein. Polyunsaturated lipids undergo oxidative decomposition to produce biogenic aldehydes, including 4-hydroxy-2-nonenal and malondialdehyde. These lipid aldehydes, some including an α,β-unsaturated carbonyl, target important proteins such as α-synuclein, proteasome degradation and G-protein-coupled signaling. Overproduction of biogenic aldehydes is a hypothesized factor in neurodegeneration; preventing their formation or scavenging may provide means for neuroprotection.

Entities:  

Keywords:  DOPAL; DOPEGAL; Parkinson’s disease; ROS; aldehydes; lipid peroxidation

Year:  2018        PMID: 31304429      PMCID: PMC6625780          DOI: 10.1016/j.cotox.2018.12.002

Source DB:  PubMed          Journal:  Curr Opin Toxicol        ISSN: 2468-2020


  11 in total

1.  3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing α-Synuclein.

Authors:  Yunden Jinsmaa; Risa Isonaka; Yehonatan Sharabi; David S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2019-11-19       Impact factor: 4.030

Review 2.  Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.

Authors:  Tapan Behl; Dapinder Kaur; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Gokhan Zengin; Felicia Liana Andronie-Cioara; Mirela Marioara Toma; Simona Bungau; Adrian Gheorghe Bumbu
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

3.  Cortical thickness is differently associated with ALDH2 rs671 polymorphism according to level of amyloid deposition.

Authors:  Yong Hyuk Cho; Heirim Lee; Na-Rae Kim; Jin Wook Choi; Hyun Woong Roh; Jae Ho Ha; Chang Hyung Hong; Sang Won Seo; Seong Hye Choi; Eun-Joo Kim; Byeong C Kim; Seong Yoon Kim; Jaeyoun Cheong; Bumhee Park; Sang Joon Son
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

4.  Characterization of Catecholaldehyde Adducts with Carnosine and l-Cysteine Reveals Their Potential as Biomarkers of Catecholaminergic Stress.

Authors:  Rachel A Crawford; Ettore Gilardoni; T Blake Monroe; Luca Regazzoni; Ethan J Anderson; Jonathan A Doorn
Journal:  Chem Res Toxicol       Date:  2021-09-10       Impact factor: 3.973

5.  Oxidative Transformations of 3,4-Dihydroxyphenylacetaldehyde Generate Potential Reactive Intermediates as Causative Agents for Its Neurotoxicity.

Authors:  Shosuke Ito; Hitomi Tanaka; Makoto Ojika; Kazumasa Wakamatsu; Manickam Sugumaran
Journal:  Int J Mol Sci       Date:  2021-10-29       Impact factor: 5.923

Review 6.  The Need to Pair Molecular Monitoring Devices with Molecular Imaging to Personalize Health.

Authors:  Zachary J Comeau; Benoît H Lessard; Adam J Shuhendler
Journal:  Mol Imaging Biol       Date:  2022-03-07       Impact factor: 3.484

Review 7.  The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Authors:  David S Goldstein
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

8.  Stable expression of the human dopamine transporter in N27 cells as an in vitro model for dopamine cell trafficking and metabolism.

Authors:  B S Cagle; M L Sturgeon; J B O'Brien; J C Wilkinson; R A Cornell; D L Roman; J A Doorn
Journal:  Toxicol In Vitro       Date:  2021-07-05       Impact factor: 3.685

9.  In vitro inhibition of glutathione-S-transferase by dopamine and its metabolites, 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid.

Authors:  Rachel A Crawford; Kate R Bowman; Brianna S Cagle; Jonathan A Doorn
Journal:  Neurotoxicology       Date:  2021-07-24       Impact factor: 4.398

Review 10.  Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine.

Authors:  Dmitriy Matveychuk; Erin M MacKenzie; David Kumpula; Mee-Sook Song; Andrew Holt; Satyabrata Kar; Kathryn G Todd; Paul L Wood; Glen B Baker
Journal:  Cell Mol Neurobiol       Date:  2021-04-10       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.